Phase 1 Refractory Cancer Clinical Trials

16 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 116 of 16 trials

Recruiting
Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1Phase 2

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics US, Inc.375 enrolled21 locationsNCT03686124
Recruiting
Phase 1

A Study of Avutometinib for People With Solid Tumor Cancers

Solid TumorSolid Tumor, AdultNeuroblastoma+12 more
Memorial Sloan Kettering Cancer Center23 enrolled2 locationsNCT06104488
Recruiting
Phase 1Phase 2

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Head and Neck CancerRecurrentRelapse+1 more
UNC Lineberger Comprehensive Cancer Center33 enrolled1 locationNCT06096038
Recruiting
Phase 1Phase 2

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 1Phase 2

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Refractory CancerRecurrent CancerChildhood Cancer+2 more
Australian & New Zealand Children's Haematology/Oncology Group90 enrolled14 locationsNCT06208657
Recruiting
Phase 1

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Metastatic Solid TumorSolid Tumor, AdultRefractory Cancer
Sairopa B.V.130 enrolled7 locationsNCT05856981
Recruiting
Phase 1

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

MelanomaHead and Neck Squamous Cell CarcinomaMetastatic Cancer+16 more
Memorial Sloan Kettering Cancer Center56 enrolled7 locationsNCT05859074
Recruiting
Phase 1Phase 2

Study of GV20-0251 in Participants With Solid Tumor Malignancies

Solid Tumor CancerAdult Refractory CancerEndometrial Carcinoma (EC)+2 more
GV20 Therapeutics350 enrolled3 locationsNCT07070518
Recruiting
Phase 1Phase 2

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

Metastatic CancerSolid TumorUnresectable Solid Tumor+3 more
Spago Nanomedical AB90 enrolled2 locationsNCT06184035
Recruiting
Phase 1Phase 2

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics Biotechnologies GmbH145 enrolled24 locationsNCT05958121
Recruiting
Phase 1

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics Biotechnologies GmbH95 enrolled23 locationsNCT05359445
Recruiting
Phase 1

A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.

Solid TumorsRefractory Cancer
Chiome Bioscience Inc.70 enrolled2 locationsNCT07016997
Recruiting
Phase 1Phase 2

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Solid Tumor, AdultCutaneous MelanomaRefractory Cancer+3 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430
Recruiting
Phase 1

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

MalignancyCancerRefractory Cancer+1 more
CytoMed Therapeutics Pte Ltd12 enrolled1 locationNCT05302037
Completed
Phase 1

Phase I trial of carboplatin in combination with irinotecan and paclitaxel split-dosed on days 1 and 8

Patients with advanced refractory cancers
Hellenic Cooperative Oncology Group20 enrolled1 locationACTRN12609000790246